ClinicalTrials.gg
RecruitingNCT07075276LPCGF in TMDsUpdated Aug 17, 2026

Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Temporomandibular Disc Displacement

An interventional study of Liquid Phase Concentrated Growth Factor and Conventional arthrocentesis in Temporomandibular Disorders (TMD), Internal Derangement of the Tempromandibular Joint and Anterior Disc Displacement, sponsored by Horus University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Horus University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Temporomandibular Joint Disorders with a site in Egypt — 10 open to participants now, 14 under way, none of them phase 3. Temporomandibular Joint Disorders · Egypt.

Planned enrollment
21st of 49
32 · median 30
Started
2025
with 7 others
No phase
42 of 63
9 open now
Primary completion
2026-11
later than 9 of 13 live
Registered
45th of 63
by date

Among the 63 studies in Temporomandibular Joint Disorders with a site in Egypt, this one is the 21st largest by planned enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2025, is one of 42 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 45th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

10 of the 63 studies in Temporomandibular Joint Disorders with a site in Egypt are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Temporomandibular Joint Disorders with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to rigorously assess the effectiveness of LPCGF in the management of internal disc displacement in patients with TMD through a randomized clinical trial. By comparing LPCGF therapy with conventional arthrocentesis, this research looks to provide robust evidence on the efficacy, safety, and potential role of (LPCGF) as an alternative therapeutic choice for IDD.

03

Conditions studied

  • Temporomandibular Disorders (TMD)
  • Internal Derangement of the Tempromandibular Joint
  • Anterior Disc Displacement

Keywords

  • Temporomandibular disorder
  • Concentrated growth factor
  • Anterior disc displacement with reduction
  • Anterior disc displacement without reduction
  • Arthrocentesis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Adults aged 18-45 years. 2. Patients scored as ().9 3. Presence of complete or nearly complete set of natural dentition with Angle class I occlusion. 4. Diagnosed with unilateral involvement of disc displacement, according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).10 5. Symptoms include one or more of the following: pain, joint sounds, and limited mandibular movement (Maximum Mouth Opening\< 40mm) 6. No prior surgical intervention for TMD. 7. Patient's willingness to participate and follow the study protocol.

Exclusion criteria

Exclusion Criteria:

  • 1. TMJ pathology related to mechanical deformities 2. Psychiatric problems or presence of systemic diseases that may affect healing (e.g., uncontrolled diabetes, disorders, hematologic or neurologic disorders, inflammatory or connective tissue disorders as well as rheumatological or previous infectious diseases, head and neck cancer). 3. Patient unwilling or has to MRI 4. Previous injections or surgical interventions of the TMJ. 5. Concurrent use of anticoagulants or anti-inflammatory medications within the last 30 days. 6. Pregnant or breastfeeding women. 7. History of trauma or infection in the TMJ region. 8. Allergy to local anesthetics or other components used in the study. 9. Patients diagnosed with (Disc Displacement with reduction with no pain or limited mandibular movements).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Group A

    16 patients have anterior disc displacement with or without reduction will be treated with injection of liquid phase concentrated growth factor

    Procedure: Liquid Phase Concentrated Growth Factor

  • Active comparator
    Group B

    16 patients have anterior disc displacement with or without reduction will be treated with conventional arthrocentesis

    Procedure: Conventional arthrocentesis

Interventions

  • ProcedureLiquid Phase Concentrated Growth Factor

    16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with injection of liquid phase concentrated growth factor

  • ProcedureConventional arthrocentesis

    16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with conventional arthrocentesis

06

What researchers measure

Primary outcomes

  1. Assess and comparing the pain of both groups

    measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain)

    Time frame: Assessed at baseline (before treatment),1week, 1 month, 3 months, and 6 months after the intervention.

  2. Assess and comparing the mouth opening of both groups

    measured in millimeters (Maximum inter-incisal opening measured by the distance in millimeters between the incisal edges of the upper and lower central incisors in vertical direction at maximum pain free mouth opening) by using caliper. and comparing the results of both groups

    Time frame: Assessed at baseline (before treatment),1week, 1 month, 3 months, and 6 months after the intervention.

Secondary outcomes

  1. Joint sounds

    (clicking and crepitus) evaluated by clinical examination; presence of joint noise at opening and closing was evaluated by light bilateral digital palpation during jaw movement.

    Time frame: Assessed at baseline (before treatment),1week, 1 month, 3 months, and 6 months after the intervention.

  2. Mandibular deviation during mouth opening.

    By clinical examination , observe mandibular deviation toward right or left side or deflection during opening and closing the mouth

    Time frame: Assessed at baseline (before treatment),1week, 1 month, 3 months, and 6 months after the intervention.

  3. Lateral and protrusive movements

    (Range of lateral and protrusive movements measured by the distance in millimeters between the upper and lower midlines in horizontal direction on lateral and protrusive movements by using caliper).

    Time frame: Assessed at baseline (before treatment),1week, 1 month, 3 months, and 6 months after the intervention

  4. tenderness on palpation

    Presence or absence of joint tenderness on palpation: recorded as tender or not tender.

    Time frame: Assessed at baseline (before treatment),1week, 1 month, 3 months, and 6 months after the intervention.

  5. TMD symptoms

    TMD symptoms were evaluated using Modified Helkimo Index

    Time frame: Assessed at baseline (before treatment),1week, 1 month, 3 months, and 6 months after the intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 13 months is above that.

Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 20, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Nov 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075276
Lead sponsor
Horus University
Responsible party
Mohamed Ali Habib (Teaching assistant, Horus University) — Principal investigator
First posted
Jul 20, 2025
Start date
Oct 1, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Aug 17, 2026

Study contacts

Mohamed Ali Habib, Teaching assistant
Contact
mbasiouny@horus.edu.eg
+2001069505336
Eman AbdElsalam Yousef, Associate professor
Contact
eabdelsalam@horus.edu.eg
+20 15 56767533
Mohamed Ali Habib, Teaching Assistant
principal investigator · Horus University in Egypt - Faculty of dentistry
Eman AbdElsalam Yousef, Ass. prof
study director · Horus University in Egypt- Faculty of dentistry
Ahmed Khalil, lecturer
study director · Horus University in Egypt - Faculty of dentistry

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion